The present work provides valuable insights for the design of small-molecule drugs aimed at destabilizing the trimeric CD137L structure or acting as CD137 agonists, providing new foundations for cancer immunotherapy and the treatment of autoimmune diseases. This evidence concerns the gene TNFRSF9 and autoimmune disease.